For many physicians, working during the holiday season is simply part of the job.

The SPIRIT H2H trial (N=566) randomized PsA patients to receive ixekizumab (160mg starting dose followed by 80mg every 4 weeks) or adalimumab (40mg every 2 weeks) for 52 weeks.

Overall, the participants reported that the facial exercise regimen was well tolerated, with 59% of the women indicating that the muscle contractions were very easy to perform.

Upadacitinib, a selective janus kinase-1 inhibitor, was associated with early improvements in pruritus in patients with moderate to severe atopic dermatitis.

Patients with atopic dermatitis have a higher likelihood of clinical depression and suicidality.

It is crucial to identify effective strategies for improving the management and control of pruritus.

In order to assess the safety and efficacy of dapsone, a sulfone antibiotic, in the treatment of CSU, the study authors reviewed the medical records of 79 CSU patients treated with dapsone.

Current treatment guidelines do not adequately cover what kind of surveillance and treatment should apply to patients with melanoma after a negative sentinel node biopsy.

Data from a Phase 2 trial of baricitinib for the treatment of SLE supporting the Fast Track designation were published in The Lancet and presented at the European Congress of Rheumatology earlier this year.

The voluntary nature of FAERS reporting can lead to both underreporting and the Weber effect, which is a decline in reports of adverse events in the 2 years after a drug appears on the market.